NCT02189499View on ClinicalTrials.gov

Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

PHASE2UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

November 30, 2020

Conditions
Coronary Artery DiseaseMyocardial Ischemia
Interventions
DEVICE

AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold

Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.

Trial Locations (4)

Unknown

Clinica de Marly, Bogotá

Instituto del Corazon, Bucaramanga

EMMSA Clinica Especializada, Medellín

Angiografia De Occidente S.A., Santiago de Cali

Sponsors
All Listed Sponsors
lead

Amaranth Medical Inc.

INDUSTRY

NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent | Biotech Hunter | Biotech Hunter